Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy

Autor: Ben-Ami, E., Barysauskas, C.M., von Mehren, M., Heinrich, M.C., Corless, C.L., Butrynski, J.E., Morgan, J.A., Wagner, A.J., Choy, E., Yap, J.T., Van den Abbeele, A.D., Solomon, S.M., Fletcher, J.A., Demetri, G.D., George, S. *
Zdroj: In Annals of Oncology September 2016 27(9):1794-1799
Databáze: ScienceDirect